An analysis of dosing equivalence of insulin detemir and insulin glargine: More evidence?

Journal of Diabetes Science and Technology

Volumn 4, Issue 1, 2010, Pages 155-157

  True, Mark W ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Continuous glucose monitoring; Detemir; Glargine; Insulin dosing; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN; INSULIN DETEMIR;

BLOOD; CIRCADIAN RHYTHM; DOSE CALCULATION; DOSE RESPONSE; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; INDIVIDUALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALITY; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC EQUIVALENCY;

EID: 77954670322     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400120     Document Type: Article

References (8)

1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
2. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-59.
3. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976-87.
4. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C. Schernthaner G. A randomised, 52-week, treat-to-target trail comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408-16.
5. Swinnen SG, Snoek FJ, Dain M, DeVries JH, Hoekstra JB, Holleman F. Rationale, design, and baseline data of the insulin glargine (lantus) versus insulin detemir (levemir) treat-to-target (l2t3) study: a multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technol Ther. 2009;11(11):739-43.
6. King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with in type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab. 2009;11(1):69-71.
7. King AB. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring. J Diabetes Sci Technol. 2009;4(1):151-4.
8. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin Resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diab Care. 2008;31(Suppl 2):S262-8.